Results 311 to 320 of about 1,213,487 (359)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Concordance index: Surrogacy of progression-free survival for overall survival
Contemporary Clinical Trials, 2021In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei Fan, Guosheng Yin
openaire +2 more sources
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer [PDF]
Journal of Clinical Oncology, 2007 Purpose The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded by the effects of second-line therapies. We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in
Langdon L. Miller +8 more
openaire +2 more sources
Progression-Free Survival: Meaningful or Simply Measurable?
Journal of Clinical Oncology, 2012The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of ...
Elizabeth Eisenhauer +1 more
openaire +3 more sources
Assessing the value of progression-free survival (AVALPROFS). [PDF]
Journal of Clinical Oncology, 2014 187 Background: Controversy exists about progression free survival (PFS) as an endpoint in novel cancer therapy trials. PFS is attractive for practical and methodological reasons but is not always a surrogate for overall survival. It is debatable whether or not PFS has discernable clinical benefit for patients (pts), the main treatment (tmt) goal ...
Lesley Fallowfield +5 more
openaire +1 more source
A statistical model for the dependence between progression‐free survival and overall survival
Statistics in Medicine, 2009AbstractAmong the surrogate endpoints for overall survival (OS) in oncology trials, progression‐free survival (PFS) is more and more taking the leading role. Although there have been some empirical investigations on the dependence structure between OS and PFS (in particular between the median OS and the median PFS), statistical models are almost non ...
Frank Fleischer +2 more
openaire +3 more sources
Progression‐free survival 2: Is it ready for prime time?
Cancer, 2022Overall survival (OS) is considered the ideal end point for clinical trials in oncology, but the emergence of postprogression therapies and the need to accelerate therapeutic development necessitate the validation of surrogate end points for OS.
Ben George, Razelle Kurzrock
openaire +2 more sources
The heterogeneity effect of surveillance intervals on progression free survival
Journal of Applied Statistics, 2022Progression-free survival (PFS) is an increasingly important surrogate endpoint in cancer clinical trials. However, the true time of progression is typically unknown if the evaluation of progression status is only scheduled at given surveillance intervals.
Zihang Zhong +6 more
openaire +2 more sources